AIM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AIM ImmunoTech Inc is not a good buy for a beginner, long-term investor at this moment. The technical indicators are bearish, the financial performance is weak, and there are no strong positive catalysts or trading signals to support a buy decision. The stock appears to be in a downtrend, and the lack of significant insider or hedge fund activity further diminishes its appeal.
The stock's MACD is negative and expanding downward, RSI indicates oversold conditions at 16.371, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with a pivot at 0.885 and current price at 0.6633, suggesting further downside potential.
The company has signed an agreement with Thermo Fisher Scientific for a Phase 3 trial of its drug Ampligen, which could be a long-term positive catalyst if successful.
The stock has experienced a significant regular market decline of -7.21%, weak financial performance in 2025/Q3 with declining revenue (-25.71% YoY), net income (-11.24% YoY), and EPS (-75.51% YoY). Gross margin is also negative and deteriorating further (-309.41% YoY).
In 2025/Q3, the company reported a revenue drop to $26,000 (-25.71% YoY), net income dropped to -$3,284,000 (-11.24% YoY), EPS dropped to -1.57 (-75.51% YoY), and gross margin dropped to -161.54 (-309.41% YoY). Overall, the financials indicate significant weakness.
No analyst rating or price target changes are provided, and there is no indication of Wall Street sentiment on the stock.
